Qing Xi Ooi supports clients with hands-on analysis and strategic advice

Viviana Moroso brings scientific depth to quality control

Siv Jönsson develops Pharmetheus’s learning agenda
Events
News

Contact us

Home
Publications

Publications

Below we provide links to posters, white papers and scientific publications by Pharmetheus affiliates in chronological order. Please note that access to some publications may require a subscription.

Search publications

Publications

23.03.23

Potential strategies to optimize CAR-T cell exposure in absence of dose-exposure relationships leveraging cell kinetic/dynamic models

Oncology

Pharmacometrics

Clin Pharmacol Ther. 2023 Feb, 113: S58

Mc Laughlin AM

22.03.23

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies

Trial design and analysis

Metabolism

Metabolism. 2023; 143.

Bianzano S, Henrich A, Herich L, Kalsch B, Sarubbi D, Seitz F, Forst T

11.02.23

Concentration QTc Analysis of Giredestrant: Overcoming QT/heart rate Confounding in the Presence of Drug-Induced Heart Rate Changes

Oncology

MIDD

Cardiovascular

Pharmacometrics

Clin Transl Sci . 2023 May;16(5):823-834

Brooks L, Dolton M, Langenhorst J, Yoshida K, Lien YTK, Malhi V, Li C, Perez-Moreno P, Bond J, Chen YC, Yu J

10.02.23

N,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner—A pharmacokinetic/pharmacodynamic analysis

Pharmacometrics

CNS

CPT Pharmacometrics Syst Pharmacol. 2023 Feb 10.

Eckernäs E, Timmermann C, Carhart-Harris R, Röshammar D, Ashton M

30.11.22

An Introduction to the Full Random Effects Model

Pharmacometrics

CPT Pharmacometrics Syst Pharmacol. 2022 Feb;11(2):149-160.

Yngman G, Bjugård Nyberg H, Nyberg J, Jonsson EN, Karlsson MO

15.11.22

Pharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Trial design and analysis

Pharmacometrics

Hematology

Blood. 2022 Nov 15; 140 (Supplement 1): 2918–2920.

Buatois S, Benkali K, Henrich A, Jaminion F, Zhang Y, Sostelly A

04.11.22

Population Pharmacokinetic Analysis of Tepotinib, an Oral MET Kinase Inhibitor, Including Data From the VISION Study

Oncology

Pharmacometrics

Cancer Chemother Pharmacol. 2022 May;89(5):655-669.

Xiong W, Papasouliotis O, Jonsson EN, Strotmann R, Girard P

03.11.22

Exposure–Response Analyses for the MET Inhibitor Tepotinib Including Patients in the Pivotal VISION Trial: Support for Dosage Recommendations

Oncology

MIDD

Pharmacometrics

Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69.

Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R

1 …181920… 34

Related content

16cefda6ef73b7faa4df913b326b6999f7619968 (1)

Science & Services

b794ade33e3aa54f89dcdaa2b69d3f48b3f73e5f (1)

Latest news

4033665f49ccf946b5c8406d016bbcdc6e406076 (1)

People & Culture

Contact

Pharmetheus AB
Kungsängstull 4  
753 19 Uppsala, Sweden

Visiting address:  
Dragarbrunnsgatan 77, 5th floor

LinkedIn
YouTube

Science & Services
Quick links

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Copyright © Pharmetheus AB 2026

Whistleblower
Privacy Policy
Cookie Policy